October 21, 2019 / 7:16 PM / a month ago

FDA approves Vertex Pharma's combo treatment for cystic fibrosis

Oct 21 (Reuters) - The U.S. Food and Drug Administration approved Vertex Pharmaceuticals Inc’s combination treatment for a rare condition called cystic fibrosis, the agency said on Monday.

The treatment, Trikafta, is a combination of three drugs that target a defective protein responsible for the life-threatening disease that builds up thick mucus in body parts such as the lungs and digestive tract. (bit.ly/2MxqCrJ) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below